BioCentury | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
BioCentury | Feb 27, 2019
Clinical News

China strengthens clinical trial approval regulations

China’s National Health Commission released draft regulations on Wednesday outlining new clinical trial approval processes for "high-risk" cellular and molecular therapeutic technologies that will increase supervision of the therapies. High-risk technologies as defined by State...
BioCentury | May 23, 2018
Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
BioCentury | May 17, 2018
Preclinical News

Targeting DOT1L, DUSP6 to prevent GvHD

In a Nature Communications study , scientists at University Health Network and University of Toronto showed that inhibiting histone methyltransferase DOT1L or promoting dual specificity phosphatase 6 (DUSP6; MKP3) could help prevent graft-versus-host disease induced by...
BioCentury | Apr 30, 2015
Distillery Therapeutics

Therapeutics: Leucine-rich repeat containing 32 (LRRC32; GARP); transforming growth factor (TGF) β 1 (TGFB1)

Cancer INDICATION: Cancer In vitro and mouse studies suggest antibodies against the GARP- TGFB1 complex could help treat cancer by suppressing Treg cells. In co-cultures of human T helper (Th) and Treg cells, two mAbs...
BioCentury | Sep 12, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscle repair Not applicable Rabbit and rodent studies suggest decellularized skeletal muscle scaffolds could be used for muscle repair without...
BioCentury | Feb 7, 2013
Tools & Techniques

Rejuvenating T cells

Two Japanese teams have used induced pluripotent stem cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. 1,2 Megakaryon Corp. is developing and commercializing the technology of one group to...
BioCentury | Feb 27, 2012
Company News

MultiCell Technologies, Rutgers University deal

The university granted MultiCell's Xenogenics Corp. subsidiary exclusive rights to a Canadian patent covering polyanhydrides and their use in creating polymeric drug delivery systems to administer low molecular-weight drugs to a host. The subsidiary said...
BioCentury | Aug 15, 2011
Company News

Caliper, Carestream Health Inc., Stanford University other news

...not market in vivo optical imaging systems for applications covered by patents Caliper and its Xenogen Corp....
...bioluminescence and X-ray imaging capabilities to image animals in preclinical testing. In February 2010, Caliper, Xenogen...
BioCentury | Feb 17, 2011
Cover Story

Fighting tumors with tumors

Researchers at The Rogosin Institute have used cancer cell-containing agarose beads to inhibit tumor proliferation in animals. 1 Although the strategy sounds counterintuitive, the macrobeads already are in an investigator-sponsored Phase II trial in patients...
Items per page:
1 - 10 of 152
BioCentury | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
BioCentury | Feb 27, 2019
Clinical News

China strengthens clinical trial approval regulations

China’s National Health Commission released draft regulations on Wednesday outlining new clinical trial approval processes for "high-risk" cellular and molecular therapeutic technologies that will increase supervision of the therapies. High-risk technologies as defined by State...
BioCentury | May 23, 2018
Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
BioCentury | May 17, 2018
Preclinical News

Targeting DOT1L, DUSP6 to prevent GvHD

In a Nature Communications study , scientists at University Health Network and University of Toronto showed that inhibiting histone methyltransferase DOT1L or promoting dual specificity phosphatase 6 (DUSP6; MKP3) could help prevent graft-versus-host disease induced by...
BioCentury | Apr 30, 2015
Distillery Therapeutics

Therapeutics: Leucine-rich repeat containing 32 (LRRC32; GARP); transforming growth factor (TGF) β 1 (TGFB1)

Cancer INDICATION: Cancer In vitro and mouse studies suggest antibodies against the GARP- TGFB1 complex could help treat cancer by suppressing Treg cells. In co-cultures of human T helper (Th) and Treg cells, two mAbs...
BioCentury | Sep 12, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscle repair Not applicable Rabbit and rodent studies suggest decellularized skeletal muscle scaffolds could be used for muscle repair without...
BioCentury | Feb 7, 2013
Tools & Techniques

Rejuvenating T cells

Two Japanese teams have used induced pluripotent stem cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. 1,2 Megakaryon Corp. is developing and commercializing the technology of one group to...
BioCentury | Feb 27, 2012
Company News

MultiCell Technologies, Rutgers University deal

The university granted MultiCell's Xenogenics Corp. subsidiary exclusive rights to a Canadian patent covering polyanhydrides and their use in creating polymeric drug delivery systems to administer low molecular-weight drugs to a host. The subsidiary said...
BioCentury | Aug 15, 2011
Company News

Caliper, Carestream Health Inc., Stanford University other news

...not market in vivo optical imaging systems for applications covered by patents Caliper and its Xenogen Corp....
...bioluminescence and X-ray imaging capabilities to image animals in preclinical testing. In February 2010, Caliper, Xenogen...
BioCentury | Feb 17, 2011
Cover Story

Fighting tumors with tumors

Researchers at The Rogosin Institute have used cancer cell-containing agarose beads to inhibit tumor proliferation in animals. 1 Although the strategy sounds counterintuitive, the macrobeads already are in an investigator-sponsored Phase II trial in patients...
Items per page:
1 - 10 of 152